A 52 wk [week] randomized, doubleblind, single dummy, parallel group multicenter phase 3 study comparing the long term safety of Symbicort [budesonide/formoterol] pMDI [pressurised metered-dose inhaler] 4x160/4.5mcg bid to SymbicortpMDI 2x160/4.5mcg Bid and budesonide HFA [hydro fluoro alkane] pMDI 4x160mcg bid in adult and adolescent subjects with asthma.
Phase of Trial: Phase III
Latest Information Update: 24 Feb 2015
At a glance
- Drugs Budesonide; Budesonide/formoterol
- Indications Asthma
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors AstraZeneca
- 17 Mar 2009 Efficacy results reported at the 65th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 22 Apr 2008 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History